Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,795 result(s) found for: cancer. Displaying page 19 of 140.
    EudraCT Number: 2014-002382-30 Sponsor Protocol Number: RDD677 Start Date*: 2015-03-13
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer:
    Medical condition: Resectable Biliary Tract Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017621 Gallbladder carcinoma localized LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034446 Periampullary carcinoma resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-022674-14 Sponsor Protocol Number: I5A-MC-JAEM Start Date*: 2011-02-25
    Sponsor Name:Lilly S.A.
    Full Title: Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con ...
    Medical condition: carcinoma de pulmón no microcítico avanzado, de histología no escamosa
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004618-93 Sponsor Protocol Number: R120502 Start Date*: 2017-12-12
    Sponsor Name:University of Manchester
    Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer
    Medical condition: Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-007152-94 Sponsor Protocol Number: 02-2008 Start Date*: 2009-01-30
    Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
    Full Title: Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study
    Medical condition: Patients affected by biliary tract cancer progressing after prior chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055111 Biliary cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001224-19 Sponsor Protocol Number: 1/0196/16 Start Date*: 2019-02-11
    Sponsor Name:Lekárska fakulta Univerzity Komenského v Bratislave
    Full Title: Non-invasive in-vivo prediction of therapeutic response to inhibitors of angiogenesis using gallium (68Ga) NODAGA-RGD PET/CT
    Medical condition: Advanced metastatic cancer of the colon or rectum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009956 Colon cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005661-11 Sponsor Protocol Number: XELOXART Start Date*: 2006-03-30
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: PHASE II STUDY OF NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062099 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019740-39 Sponsor Protocol Number: COMEDIANS Start Date*: 2010-04-26
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Isotonic contrast (iodixanol) administration vs. low osmolar contrast (iopromide) use: evaluating risk of contrast-induced nephropathy in cancer patients at very low risk
    Medical condition: Oncological patients undergoing to diagnostic imaging
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022893 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005087-14 Sponsor Protocol Number: CPP-401 Start Date*: 2008-11-12
    Sponsor Name:Centre Paul Papin
    Full Title: Comparison of 2 morphine administration’s mode using Pump IntraThecal (IDDS)for Analgesia in patients with Cancer pain, resistant to conventional antalgic treatment
    Medical condition: Patients with intractable cancer pain, either uncontrolled with standard analgesia , or undergoing severe side effects due to analgesia . Patients undergo implantation of a Medtronic intrathecal pu...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058019 Cancer pain LLT
    9.1 10059050 Intractable pain LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003048-31 Sponsor Protocol Number: P070404 Start Date*: 2007-10-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel.
    Medical condition: -Patients présentant un cancer de la prostate métastatique hormono-résistant en progression après une 1ère ligne de traitement par docétaxel.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Cancer de la prostate PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002470-40 Sponsor Protocol Number: PROSORA Start Date*: 2017-11-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study)
    Medical condition: patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003814-14 Sponsor Protocol Number: ML19498 Start Date*: 2006-03-13
    Sponsor Name:Unidad Integral de Investigación en Oncología, S.L.
    Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002886-11 Sponsor Protocol Number: BEBYP Start Date*: 2008-01-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLU...
    Medical condition: METASTATIC COLORECTAL CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018491-24 Sponsor Protocol Number: 31295 Start Date*: 2010-07-15
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells
    Medical condition: patients with malignant bone metastases
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021962-31 Sponsor Protocol Number: Protocolversion1-20100713 Start Date*: 2011-10-06
    Sponsor Name:Bo Lennernäs
    Full Title: KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC)
    Medical condition: Men with castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001332-35 Sponsor Protocol Number: AX-CL-PANC-PI-0006859 Start Date*: 2017-03-20
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer
    Medical condition: Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001369-27 Sponsor Protocol Number: PACLIDOX 07 Start Date*: 2008-02-12
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER
    Medical condition: Operable breast cancer patients (T>2 cm, cT2-3, N0-N2, M0) or potentially operable, locally advanced breast cancer patients (T4, N0-2, M0) or inflammatory breast cancer patients (T4d, N0-2, M0), wi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006290 Breast and nipple neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005431-86 Sponsor Protocol Number: FuTuRe Start Date*: 2014-02-10
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
    Medical condition: Castration-resistant prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003189-29 Sponsor Protocol Number: ONCO-01-2017 Start Date*: 2018-02-09
    Sponsor Name:L'Institut Mutualiste Montsouris
    Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001428-23 Sponsor Protocol Number: M17GEL Start Date*: 2017-09-29
    Sponsor Name:NKI-AVL
    Full Title: AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024745 Lobular breast carcinoma invasive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002480-94 Sponsor Protocol Number: 69HCL17_0342 Start Date*: 2021-07-21
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Assessment of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in first or secondary platinum-resistant recurrent ovarian epithelial cancer. HIPOVA-01
    Medical condition: Patients with First or second recurrence of platin-resistant epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:27:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA